Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Benjamin T Dake. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Benjamin T Dake har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:AVTE / Aerovate Therapeutics, Inc. | SEE REMARKS | 14 252 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Benjamin T Dake. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Benjamin T Dake som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-08-02 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | 1 507 | 14 252 | 11,82 | 1,74 | 2 622 | 24 798 | |
2024-08-02 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | 11 454 | 12 745 | 887,22 | 1,74 | 19 930 | 22 176 | |
2024-04-19 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −68 | 1 291 | −5,00 | 23,97 | −1 630 | 30 945 |
2024-04-19 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −338 | 1 359 | −19,92 | 23,17 | −7 831 | 31 488 |
2024-04-19 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −6 447 | 1 697 | −79,16 | 22,32 | −143 865 | 37 869 |
2024-04-19 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 6 853 | 8 144 | 530,83 | 2,14 | 14 665 | 17 428 |
2024-04-03 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −3 325 | 1 291 | −72,03 | 31,97 | −106 317 | 41 280 |
2024-04-03 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 3 325 | 4 616 | 257,55 | 10,61 | 35 278 | 48 976 |
2024-03-28 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −11 068 | 1 291 | −89,55 | 27,97 | −309 519 | 36 103 |
2024-03-28 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 11 068 | 12 359 | 857,32 | 10,61 | 117 431 | 131 129 |
2024-03-27 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −3 432 | 1 291 | −72,67 | 28,01 | −96 119 | 36 157 |
2024-03-27 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 3 432 | 4 723 | 265,84 | 10,61 | 36 414 | 50 111 |
2024-03-20 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −7 581 | 1 291 | −85,45 | 26,48 | −200 764 | 34 189 |
2024-03-20 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −27 476 | 8 872 | −75,59 | 25,74 | −707 282 | 228 381 |
2024-03-20 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 14 500 | 36 348 | 66,37 | 10,61 | 153 845 | 385 652 |
2024-03-20 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 20 557 | 21 848 | 1 592,33 | 2,14 | 43 992 | 46 755 |
2023-12-07 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −10 283 | 1 291 | −88,85 | 16,11 | −165 628 | 20 794 |
2023-12-07 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 872 | 11 574 | 212,64 | 2,14 | 16 846 | 24 768 |
2023-12-07 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 2 411 | 3 702 | 186,75 | 1,74 | 4 195 | 6 441 |
2023-11-29 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −12 517 | 1 291 | −90,65 | 16,24 | −203 237 | 20 962 |
2023-11-29 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 10 104 | 13 808 | 272,79 | 2,14 | 21 623 | 29 549 |
2023-11-29 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 2 413 | 3 704 | 186,91 | 1,74 | 4 199 | 6 445 |
2023-11-27 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −70 | 1 291 | −5,14 | 16,07 | −1 125 | 20 741 |
2023-11-27 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −4 920 | 1 361 | −78,33 | 15,74 | −77 423 | 21 417 |
2023-11-27 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 4 990 | 6 281 | 386,52 | 2,14 | 10 679 | 13 441 |
2023-11-27 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −9 382 | 1 291 | −87,90 | 15,17 | −142 359 | 19 589 |
2023-11-27 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 6 970 | 10 673 | 188,23 | 2,14 | 14 916 | 22 840 |
2023-11-27 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 2 412 | 3 703 | 186,83 | 1,74 | 4 197 | 6 443 |
2023-09-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −30 | 1 291 | −2,27 | 15,01 | −450 | 19 378 |
2023-09-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 30 | 1 321 | 2,32 | 2,14 | 64 | 2 827 |
2023-09-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −3 931 | 1 291 | −75,28 | 15,06 | −59 187 | 19 438 |
2023-09-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 1 518 | 5 222 | 40,98 | 2,14 | 3 249 | 11 175 |
2023-09-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 2 413 | 3 704 | 186,91 | 1,74 | 4 199 | 6 445 |
2023-08-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −541 | 1 291 | −29,53 | 16,25 | −8 789 | 20 972 |
2023-08-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −9 742 | 1 832 | −84,17 | 15,48 | −150 792 | 28 357 |
2023-08-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 871 | 11 574 | 212,56 | 2,14 | 16 844 | 24 768 |
2023-08-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 2 412 | 3 703 | 186,83 | 1,74 | 4 197 | 6 443 |
2023-07-07 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −10 283 | 1 291 | −88,85 | 16,66 | −171 284 | 21 504 |
2023-07-07 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 871 | 11 574 | 212,56 | 2,14 | 16 844 | 24 768 |
2023-07-07 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 2 412 | 3 703 | 186,83 | 1,74 | 4 197 | 6 443 |
2023-06-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −15 | 1 291 | −1,15 | 16,98 | −255 | 21 915 |
2023-06-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −10 268 | 1 306 | −88,72 | 16,28 | −167 161 | 21 261 |
2023-06-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 871 | 11 574 | 212,56 | 2,14 | 16 844 | 24 768 |
2023-06-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 2 412 | 3 703 | 186,83 | 1,74 | 4 197 | 6 443 |
2023-05-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −1 599 | 1 291 | −55,33 | 22,74 | −36 355 | 29 352 |
2023-05-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −8 685 | 2 890 | −75,03 | 21,62 | −187 805 | 62 494 |
2023-05-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 871 | 11 575 | 212,50 | 2,14 | 16 844 | 24 770 |
2023-05-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 2 413 | 3 704 | 186,91 | 1,74 | 4 199 | 6 445 |
2023-04-07 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −10 283 | 0 | −100,00 | 18,17 | −186 829 | |
2023-04-07 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 871 | 10 283 | 326,33 | 2,14 | 16 844 | 22 006 |
2023-04-07 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 2 412 | 2 412 | 1,74 | 4 197 | 4 197 | |
2023-03-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −215 | 0 | −100,00 | 24,50 | −5 267 | |
2023-03-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −10 067 | 215 | −97,91 | 23,71 | −238 687 | 5 098 |
2023-03-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 870 | 10 282 | 326,29 | 2,14 | 16 842 | 22 003 |
2023-03-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 2 412 | 2 412 | 1,74 | 4 197 | 4 197 | |
2023-02-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −1 426 | 0 | −100,00 | 25,02 | −35 679 | |
2023-02-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −8 858 | 1 426 | −86,13 | 24,52 | −217 203 | 34 966 |
2023-02-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 872 | 10 284 | 326,37 | 2,14 | 16 846 | 22 008 |
2023-02-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 2 412 | 2 412 | 1,74 | 4 197 | 4 197 | |
2023-01-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −2 792 | 0 | −100,00 | 26,95 | −75 254 | |
2023-01-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −7 492 | 2 792 | −72,85 | 25,62 | −191 949 | 71 532 |
2023-01-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 871 | 10 284 | 326,19 | 2,14 | 16 844 | 22 008 |
2023-01-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 2 413 | 2 413 | 1,74 | 4 199 | 4 199 | |
2022-12-14 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −907 | 0 | −100,00 | 30,26 | −27 443 | |
2022-12-14 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −1 132 | 907 | −55,52 | 28,83 | −32 632 | 26 146 |
2022-12-14 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −20 | 2 039 | −0,97 | 25,82 | −516 | 52 647 |
2022-12-14 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 2 059 | 2 059 | 2,14 | 4 406 | 4 406 | |
2022-12-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −394 | 0 | −100,00 | 25,03 | −9 861 | |
2022-12-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 394 | 394 | 2,14 | 843 | 843 | |
2022-12-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −3 178 | 0 | −100,00 | 24,08 | −76 533 | |
2022-12-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −3 199 | 3 178 | −50,16 | 22,56 | −72 178 | 71 705 |
2022-12-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −2 695 | 6 377 | −29,71 | 21,63 | −58 302 | 137 957 |
2022-12-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −928 | 9 072 | −9,28 | 20,94 | −19 435 | 189 996 |
2022-12-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 10 000 | 10 000 | 2,14 | 21 400 | 21 400 | |
2022-12-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −615 | 0 | −100,00 | 18,29 | −11 250 | |
2022-12-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −36 115 | 615 | −98,33 | 17,80 | −642 861 | 10 947 |
2022-12-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −1 259 | 36 730 | −3,31 | 16,90 | −21 275 | 620 678 |
2022-12-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −2 011 | 37 989 | −5,03 | 15,61 | −31 386 | 592 906 |
2022-12-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 37 588 | 40 000 | 1 558,37 | 2,14 | 80 438 | 85 600 |
2022-12-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 2 412 | 2 412 | 1,74 | 4 197 | 4 197 | |
2022-11-14 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −121 | 0 | −100,00 | 22,20 | −2 686 | |
2022-11-14 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −1 625 | 121 | −93,07 | 21,41 | −34 796 | 2 591 |
2022-11-14 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −4 452 | 1 746 | −71,83 | 20,39 | −90 754 | 35 592 |
2022-11-14 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 6 198 | 6 198 | 2,14 | 13 264 | 13 264 | |
2022-11-14 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −1 800 | 0 | −100,00 | 20,10 | −36 172 | |
2022-11-14 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 1 800 | 1 800 | 2,14 | 3 852 | 3 852 | |
2022-11-14 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −14 000 | 0 | −100,00 | 17,91 | −250 677 | |
2022-11-14 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 14 000 | 14 000 | 2,14 | 29 960 | 29 960 | |
2022-11-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −8 373 | 0 | −100,00 | 18,09 | −151 458 | |
2022-11-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 8 373 | 8 373 | 2,14 | 17 918 | 17 918 | |
2022-11-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −1 660 | 0 | −100,00 | 20,24 | −33 594 | |
2022-11-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −1 486 | 1 660 | −47,23 | 19,57 | −29 081 | 32 486 |
2022-11-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −3 359 | 3 146 | −51,64 | 18,58 | −62 399 | 58 443 |
2022-11-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −11 122 | 6 505 | −63,10 | 17,79 | −197 819 | 115 700 |
2022-11-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 15 214 | 17 627 | 630,50 | 2,14 | 32 558 | 37 722 |
2022-11-09 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 2 413 | 2 413 | 1,74 | 4 199 | 4 199 | |
2022-10-20 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −5 705 | 0 | −100,00 | 21,08 | −120 287 | |
2022-10-20 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 5 705 | 5 705 | 2,14 | 12 209 | 12 209 | |
2022-10-18 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −4 185 | 0 | −100,00 | 20,16 | −84 380 | |
2022-10-18 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 4 185 | 4 185 | 2,14 | 8 956 | 8 956 | |
2022-10-18 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −110 | 0 | −100,00 | 20,05 | −2 206 | |
2022-10-18 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 110 | 110 | 2,14 | 235 | 235 | |
2022-10-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −1 430 | 0 | −100,00 | 17,26 | −24 689 | |
2022-10-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −3 524 | 1 430 | −71,13 | 16,74 | −58 992 | 23 938 |
2022-10-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 4 954 | 4 954 | 2,14 | 10 602 | 10 602 | |
2022-10-11 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −1 757 | 0 | −100,00 | 16,41 | −28 828 | |
2022-10-11 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −8 763 | 1 757 | −83,30 | 15,93 | −139 631 | 27 996 |
2022-10-11 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 10 520 | 10 520 | 2,14 | 22 513 | 22 513 | |
2022-10-11 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −948 | 0 | −100,00 | 17,31 | −16 411 | |
2022-10-11 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −882 | 948 | −48,20 | 16,54 | −14 589 | 15 680 |
2022-10-11 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −11 210 | 1 830 | −85,97 | 15,64 | −175 345 | 28 624 |
2022-10-11 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 10 629 | 13 040 | 440,85 | 2,14 | 22 746 | 27 906 |
2022-10-11 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 2 411 | 2 411 | 1,74 | 4 195 | 4 195 | |
2022-09-14 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −272 | 0 | −100,00 | 18,77 | −5 105 | |
2022-09-14 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −1 976 | 272 | −87,90 | 18,26 | −36 087 | 4 967 |
2022-09-14 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −5 272 | 2 248 | −70,11 | 16,90 | −89 115 | 37 999 |
2022-09-14 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 520 | 7 520 | 2,14 | 16 093 | 16 093 | |
2022-09-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −176 | 0 | −100,00 | 18,54 | −3 262 | |
2022-09-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −4 544 | 176 | −96,27 | 17,50 | −79 540 | 3 081 |
2022-09-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 4 462 | 4 720 | 1 729,46 | 2,14 | 9 549 | 10 101 |
2022-09-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 258 | 258 | 1,74 | 449 | 449 | |
2022-09-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −629 | 0 | −100,00 | 18,42 | −11 588 | |
2022-09-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −2 491 | 629 | −79,84 | 18,14 | −45 193 | 11 412 |
2022-09-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 3 120 | 3 120 | 1,74 | 5 429 | 5 429 | |
2022-09-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −3 658 | 0 | −100,00 | 18,42 | −67 386 | |
2022-09-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −5 | 3 658 | −0,12 | 18,12 | −83 | 66 270 |
2022-09-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 8 220 | 8 220 | 1,74 | 14 303 | 14 303 | |
2022-09-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −606 | 0 | −100,00 | 19,78 | −11 984 | |
2022-09-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −4 138 | 606 | −87,23 | 18,98 | −78 546 | 11 503 |
2022-09-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −4 422 | 4 744 | −48,24 | 17,94 | −79 345 | 85 123 |
2022-09-08 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 9 166 | 9 166 | 1,74 | 15 949 | 15 949 | |
2022-08-18 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −3 451 | 0 | −100,00 | 24,10 | −83 174 | |
2022-08-18 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −7 074 | 3 451 | −67,21 | 23,29 | −164 724 | 80 360 |
2022-08-18 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −10 475 | 10 525 | −49,88 | 22,44 | −235 034 | 236 156 |
2022-08-18 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 21 000 | 21 000 | 1,74 | 36 540 | 36 540 | |
2022-08-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −79 | 0 | −100,00 | 24,55 | −1 939 | |
2022-08-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −1 268 | 79 | −94,14 | 23,89 | −30 292 | 1 887 |
2022-08-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 1 347 | 1 347 | 1,74 | 2 344 | 2 344 | |
2022-08-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −780 | 0 | −100,00 | 24,48 | −19 096 | |
2022-08-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −11 940 | 780 | −93,87 | 24,06 | −287 270 | 18 766 |
2022-08-12 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 12 720 | 12 720 | 1,74 | 22 133 | 22 133 | |
2022-08-10 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −2 791 | 0 | −100,00 | 24,52 | −68 436 | |
2022-08-10 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −5 909 | 2 791 | −67,92 | 23,84 | −140 889 | 66 546 |
2022-08-10 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 8 700 | 8 700 | 1,74 | 15 138 | 15 138 | |
2022-08-10 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −2 954 | 0 | −100,00 | 24,94 | −73 678 | |
2022-08-10 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
S - Sale | X | −3 989 | 2 954 | −57,45 | 24,39 | −97 283 | 72 042 |
2022-08-10 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Common Stock |
M - Exercise | X | 6 943 | 6 943 | 1,74 | 12 081 | 12 081 | |
2021-12-16 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 58 000 | 58 000 | |||||
2021-07-01 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 180 800 | 180 800 | |||||
2021-07-01 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 328 921 | 328 921 | |||||
2021-07-01 |
|
4 | AVTE |
Aerovate Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 48 882 | 48 882 |